The Association for Molecular Pathology (AMP) has published a set of 13 best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and ...

Dr. Stephen will cover the process of developing and manufacturing reliable Luminex biomarker assays, as well as using those assays to test samples. She will examine the development of Ampersand ...

A new wave of automated, inexpensive, and high-throughput multiplexing technologies has been widely reported on of late. Diagnostic laboratories and clinical pharmacologists will find these ...

Understand the importance of targeted assays in personalised medicine and how early decisions shape clinical outcomes.

Spatial analysis of protein or gene expression is vital to understanding the distribution, phenotypes, and interactions between cells within tumor microenvironment (TME). Traditionally, multiplexed ...

Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer The two droplet digital polymerase chain reaction assays reported VAF values very close to the ...

Summit™ 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...

A LAMP-based, visually read assay enables rapid FSHR N680S genotyping from buccal swabs, potentially allowing pre-cycle selection of recombinant FSH versus hMG to optimize ovarian stimulation.

A new chapter is unfolding for gene therapies in Europe. With retinal programs advancing into Phase I/II trials and ...